Gilead

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

Retrieved on: 
Sunday, June 5, 2022
Immunotherapy, Penile cancer, Head, HNSCC, Cell, Society, Lung, RECIST, HPV16, Food, Progression-free survival, Vulvar cancer, Standard of care, Human papillomavirus infection, Degenerative disease, Cancer, ASCO, Annual general meeting, Prostate cancer, CD8, Pembrolizumab, American Society of Clinical Oncology, Prostate, Therapy, GLOBE, Patient, Fast track (FDA), HBV, Technology, Arenavirus, E7, DNA, HPV, NASDAQ, NEW, Clinical trial, Population, HIV, Neck, Gilead, Protein, KRAS, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD Anderson Cancer Center, Person, Safety, Lymphocytic choriomeningitis, Vaccine, Pharmaceutical industry

The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • These results help focus our efforts as we move HB-202/HB-201 at the recommended Phase 2 dose into the Phase 2 portion of the trial.
  • Sixty-eight patients with advanced HPV16+ cancers were treated in the Phase 1 trial as of March 31, 2022.
  • Fifty-four patients had advanced HPV16+ head and neck cancers with a median of three prior therapies (range of 1-11), including a checkpoint inhibitor regimen in 50 of the 54.

GentiBio Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

Retrieved on: 
Wednesday, June 1, 2022
Filgotinib, Albert Einstein College of Medicine, Research, Knowledge, Doctor of Philosophy, Inflammation, Senior, Therapy, University, Autoimmunity, Immunology, Patient, AbbVie, MS, Immune system, University of Washington Department of Global Health, Immune tolerance, Overactive bladder, Degenerative disease, Drug development, Gilead, Adalimumab, Vaccine, Regulatory T cell, MD

CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced that Neely Mozaffarian, M.D., Ph.D., has been appointed to the position of Chief Medical Officer. Bringing more than 25 years of clinical and management experience in autoimmunity research, Dr. Mozaffarian will oversee the company's growing clinical and regulatory organization.

Key Points: 
  • CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced that Neely Mozaffarian, M.D., Ph.D., has been appointed to the position of Chief Medical Officer.
  • Bringing more than 25 years of clinical and management experience in autoimmunity research, Dr. Mozaffarian will oversee the company's growing clinical and regulatory organization.
  • Neely received her MD and PhD degrees from Albert Einstein College of Medicine and completed her internal medicine residency training and rheumatology fellowship at the University of Washington.
  • "I'm excited to join GentiBio to lead the experienced clinical and regulatory team as we are poised to become a clinical-stage company," stated Dr. Mozaffarian.

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Retrieved on: 
Thursday, May 26, 2022
Cancer, DNA, Degenerative disease, Immunotherapy, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBV, Food, Vulvar cancer, NEW, KRAS, Progression-free survival, HPV16, Patient, Science, Prostate, Gilead, NASDAQ, PD-1, RECIST, Fast track (FDA), CD8, Clinical trial, Society, Penile cancer, American Society of Clinical Oncology, Cell, HNSCC, Pembrolizumab, Arenavirus, Prostate cancer, Neck, Technology, Safety, Biomarker, ASCO, Standard of care, Lymphocytic choriomeningitis, Head, Lung, Human papillomavirus infection, Protein, HIV, E7, HPV, GLOBE, Medical imaging, Pharmaceutical industry, Online shopping, Vaccine

We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.

Key Points: 
  • We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.
  • The final analysis shows that HB-201 and 2-vector HB-202/HB-201 were generally well tolerated and showed anti-tumor activity in these difficult-to-treat patients.
  • The primary endpoint of Phase 1 is a recommended Phase 2 dose.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022

Retrieved on: 
Thursday, May 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Triple-negative breast cancer, TREM2, MTD, Myelocyte, Trae tha Truth, Immunotherapy, Neoplasm, Annual general meeting, HER2, TAM, Tams, Tumor microenvironment, Patient, Poster, Gilead, TME, Sofinnova, Macrophage, Pharmacokinetics, Society, Half-life, CD8, American Society of Clinical Oncology, Pembrolizumab, Metastasis, Index (publishing), Immunity, Adenocarcinoma, Safety, Monoclonal antibody, TREM1, ASCO, EVP, Large-cell lung carcinoma, Ovarian cancer, Oncology nursing, New Enterprise Associates, Colorectal cancer, Therapy, Tumor-associated macrophage, Renal cell carcinoma, Cancer, PK, Immunosuppression, Immunoglobulin G, ADCC, Gilead Sciences, Vaccine, Pharmaceutical industry, Medical imaging, Pionýr

The study will be featured in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7 virtually and in Chicago.

Key Points: 
  • The study will be featured in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7 virtually and in Chicago.
  • Pionyr developed PY314 to precisely bind human TREM2 and retune the tumor microenvironment by driving the selective depletion of TREM2 positive tumor-associated macrophages.
  • We have applied what we have learned from the Phase 1a study to identify a recommended dose for Phase 1b expansion studies.
  • The Phase 1a dose-escalation study of PY314 was a non-randomized, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PY314 as a single agent and in combination with checkpoint inhibitor pembrolizumab in 28 subjects with advanced solid tumors.

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress

Retrieved on: 
Wednesday, May 25, 2022
Joint, Product, UC, Disease, Medicine, Galapagos NV, BMI, Interview, Eisai, Tablet, Fatigue, CEST, Physician, Filgotinib, Pain, Swelling, Contraindication, Gilead, EULAR, European, Research, Ministry of Health, Labour and Welfare, MTX, Inflammation, TBC, Euronext, 2021 Essex County Council election, Goal, Adult, JAK, Fibrosis, European League Against Rheumatism, Heart, MD, Physical disability, Disease-modifying antirheumatic drug, Ageing, LTE, Patient, Rheumatoid arthritis, Human, Safety, Union, CET, Lymphocyte, Methotrexate, Gilead Sciences, Pharmaceutical industry, Frankincense, Fireworks, Galápagos Islands, Health

Mechelen, Belgium; 25 May 2022, 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.

Key Points: 
  • Mechelen, Belgium; 25 May 2022, 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.
  • A meet-the-expert session, Patient-centred care in RA: cutting through the jargon will feature insights and answers to audience questions on putting patients at the heart of their RA care.
  • Additionally, Galapagos will present preclinical data on selective SIK3 (salt-inducible kinase) inhibition as a novel mode of action for the treatment of RA.
  • Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, May 11, 2022
Carcinoma, Cancer, Mutation, PRMT5, Safety, Collaboration, Human, Annual report, SEC, Technology, Forward-looking statement, Immune system, NASDAQ, Company, ESMO, Patient, Risk, Clinical trial, Program, FDA, American Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast, Oncology, Congress, Research, Large-cell lung carcinoma, Therapy, European Society for Medical Oncology, Mesothelioma, Neoplasm, Time, Association, Gilead, Intellectual property, Goal, AACR, Cell, COVID-19, MTAP, FTD, American Association for Cancer Research, GLOBE, USP1, Food, Review, Fast track (FDA), Patent, Precision medicine, Cervical cancer, Investigational New Drug, STK11, Traffic barrier, Terminology, KRAS, Pharmaceutical industry, Vaccine, Online gambling, Cholangiocarcinoma, GBM, IND, Glioblastoma, IND World's Fair Line

CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2022 and provided business highlights.

Key Points: 
  • Weve had a strong start to 2022, including IND clearance and Fast Track Designation from the FDA for TNG908, our lead PRMT5 inhibitor program.
  • As disclosed in January 2022, the FDA cleared the Investigational New Drug (IND) application for TNG908.
  • Presented preclinical data on TNG908, USP1 inhibitor program and discovery platform at 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

Retrieved on: 
Monday, May 9, 2022
Prostate cancer, Company, CD8, Arenavirus, HIV, HBV, Gilead, KRAS, Cancer, NASDAQ, GLOBE, Lung, Vaccine

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.

Key Points: 
  • NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.
  • The Company will not be conducting a conference call in conjunction with this earnings release.
  • HOOKIPAs replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

Retrieved on: 
Tuesday, May 3, 2022
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Nexus, Investment, LabCorp, Forty-seven rōnin, Fred Hutchinson Cancer Research Center, NASDAQ, Fund, Partnership, CMPS, NYSE, Patient, Bristol Myers Squibb, Cancer, Gilead, Celgene, Oaktree Capital Management, Juno Therapeutics, Johns Hopkins University, Exact sciences, EfTEN Real Estate Fund III, Biomedical technology, Johns Hopkins, Therapy, Growth, LH, IPO, Johns Hopkins School of Medicine, Foundation, Financial services, Pharmaceutical industry, Fine chemical, LP, Research, Octant, Series

Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (Fund III or the Fund), with more than $381 million in total capital commitments, exceeding its original $300 million target.

Key Points: 
  • Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (Fund III or the Fund), with more than $381 million in total capital commitments, exceeding its original $300 million target.
  • The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.
  • Previously, Catalio raised $15 million for Nexus Fund I and $100 million for Nexus Fund II.
  • Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights.

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

Retrieved on: 
Tuesday, May 3, 2022
Arenavirus, NASDAQ, GLOBE, HBV, Bank of America, Lung, HIV, CD8, Gilead, Webcast, Prostate cancer, Conference, Cancer, KRAS, Investor, Vaccine

Archived replays will be accessible for 30 days following each event.

Key Points: 
  • Archived replays will be accessible for 30 days following each event.
  • HOOKIPAs replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
  • HOOKIPAs pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer

Retrieved on: 
Monday, May 2, 2022
Board, Drug development, Arenavirus, COO, Private Securities Litigation Reform Act, Offering, Dartmouth College, Aptitude, NASDAQ, GLOBE, Annual report, HBV, Christine, Lung, HIV, CD8, Risk, Business development, Form 10-K, Gilead, Novartis, Marketing, Hotel manager, Prostate cancer, Rutgers University, MBA, Science, Schering-Plough, U.S. Securities and Exchange Commission, Growth, KRAS, Cancer

NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.

Key Points: 
  • NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.
  • Christine has also helped establish and grow our US-based operations, which will continue to play a key role in our future growth.
  • Christine D. Baker has more than 30 years experience in the biotech/pharmaceutical industry, with expertise in business development, commercialization, and drug development strategies.
  • Prior to joining HOOKIPA, Christine served as Chief Business Officer at EpicentRx and Vice President at Novartis Oncology.